2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…2016 American Transplant Congress
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.
Northwestern University, Chicago, IL; University of Virginia, Chicago, IL.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Stratification of Kidney Transplant Recipients into Those with Low and High Alloreactive T-Cells May Allow Safe Conversion to mTOR-Inhibitor-Based Immunosuppression.
ZEUS and Herakles study randomized kidney transplant recipients (KTRs) to either continue cyclosporine or convert to everolimus posttransplantation with favorable long-term outcomes in the conversion…2016 American Transplant Congress
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.
PURPOSE: RDP after KTx is associated with increased early rejection; no decrease in medium‐term patient (PS) or graft survival (GS); and significantly decreased prednisone‐related side…2016 American Transplant Congress
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.
ELEVATE study group, Leiden, Netherlands.
Background: Several studies reported that recipients receiving renal allograft from living donors have better efficacy outcomes than the deceased donor counterparts. This post-hoc analysis of…2016 American Transplant Congress
A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with non-expressers. This randomized-controlled study investigated if…2016 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.
Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…2016 American Transplant Congress
How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.
Purpose:To investigate the effect of tacrolimus(tac) variability on the development of Donor Specific Antibodies(DSA),rejection and outcome in relation to Age, Gender, Ethnicity and Body Mass…2016 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy improves outcomes in kidney transplant recipients (KTRs) by reducing early acute rejection. In the current era of potent maintenance immunosuppression, the role of…2016 American Transplant Congress
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect…
American Transplant Congress abstracts